NCT07029009RecruitingPhase 2
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Aug 2024
- Start date
- 8 May 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Mansa
- Diseases
- Type 2 diabetes
- NCT number
- NCT07029009
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 8 May 2025 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- on medications within the stimulant class
- have had bariatric surgery
Other illness
- History of anaphylaxis to GLP-1 receptor agonists
- personal or family history of cancer, especially medullary thyroid cancer
- personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
- known active kidney disease
Lab values
- severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment
- HbA1c \> 10.0%
Other
- Already taking GLP-1 receptor agonists
- episode of diabetic ketoacidosis (DKA) in the past 3 months
- are currently pregnant
- BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile
Who the study is looking for
- Diagnosis of MODY via genetic testing
- HgbA1c \>6.5%
Age in the registry: 10 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.